BHC(SH:600721)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 58,796,482.88, representing a year-on-year increase of 24.40%[5] - The net profit attributable to shareholders for the same period was CNY 1,372,156.64, up 28.00% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 122.20% to CNY 945,756.27[5] - Basic earnings per share for the quarter were CNY 0.0037, an increase of 27.59% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥58,796,482.88, a 24.3% increase from ¥47,264,446.74 in Q1 2021[15] - Net profit for Q1 2022 was ¥1,378,890.58, representing a 27.3% increase compared to ¥1,083,387.72 in Q1 2021[15] - The basic earnings per share for Q1 2022 was ¥0.0037, up from ¥0.0029 in Q1 2021[16] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -12,682,485.50, reflecting a decrease of 6.89%[5] - Cash flow from operating activities showed a net outflow of ¥12,682,485.50, an improvement from a net outflow of ¥13,620,328.17 in Q1 2021[17] - The company reported a decrease in cash and cash equivalents to CNY 49,289,567.66 from CNY 86,884,849.85, a decline of approximately 43.0%[11] - Cash and cash equivalents at the end of Q1 2022 totaled ¥49,289,567.66, compared to ¥41,785,041.34 at the end of Q1 2021[18] Research and Development - The company's research and development expenses increased by 282.09% compared to the same period last year, indicating a significant investment in R&D[7] - Research and development expenses rose significantly to ¥4,354,071.54, up 282.5% from ¥1,139,542.38 in Q1 2021[15] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[15] Liabilities and Equity - The total liabilities decreased to CNY 293,293,913.94 from CNY 296,060,953.02, representing a reduction of approximately 0.9%[13] - The company's total equity increased to CNY 687,630,952.45 as of March 31, 2022, compared to CNY 686,252,061.87 at the end of 2021, showing a growth of about 0.2%[13] - The total liabilities to equity ratio as of March 31, 2022, was approximately 0.43, indicating a relatively stable leverage position[13] Inventory and Receivables - Inventory as of March 31, 2022, was CNY 203,632,250.60, up from CNY 194,047,820.84, marking an increase of approximately 4.1%[11] - Accounts receivable rose to CNY 21,180,170.24 from CNY 17,759,114.68, reflecting an increase of about 19.3%[11] Government Subsidies and Expenses - The company received government subsidies amounting to CNY 388,403.94, which were closely related to its normal business operations[7] - Sales expenses rose by 130.88%, primarily due to the expansion of the sales team at Lihua Bio[7]